American heart journal最新文献

{"title":"Association Between Hospital Ownership Type and ST-Segment Elevation Myocardial Infarction Outcomes: Insights from the National Readmission Database, 2016-2022.","authors":"Olivia C Liu, John Billings, Jason N Katz, Sunil V Rao, Carlos Alviar, Sripal Bangalore, Orly Leiva","doi":"10.1016/j.ahj.2026.107452","DOIUrl":"https://doi.org/10.1016/j.ahj.2026.107452","url":null,"abstract":"<p><strong>Background: </strong>Hospital ownership type may influence acute cardiovascular disease disparities that persist across the U.S. We examined associations between hospital ownership type and in-hospital and readmission outcomes for STEMI hospitalizations.</p><p><strong>Methods: </strong>We performed a retrospective cohort study of hospitalizations for STEMI using the National Readmissions Database (2016-2022). Hospitals were categorized as nonprofit, for-profit, or public. Outcomes included in-hospital mortality and 90-day readmission for acute coronary syndrome, heart failure, cardiovascular, and all causes. Associations were assessed using multivariable logistic and Cox proportional hazards regression, adjusting for patient, hospitalization, and hospital-level characteristics.</p><p><strong>Results: </strong>Of 610,427 STEMI hospitalizations, 460,451 (75.4%) were at nonprofit, 88,965 (14.6%) at for-profit, and 61,011 (10.0%) at public hospitals. Compared with nonprofit hospitals, for-profit hospitals (aOR 1.09, 95% CI 1.05-1.13) and public hospitals (aOR 1.17, 95% CI 1.12-1.22) were each associated with higher odds of in-hospital mortality. For-profit hospitals were associated with higher risk of 90-day readmission for acute coronary syndrome (aHR 1.15, 95% CI 1.10-1.21), heart failure (aHR 1.08, 95% CI 1.03-1.13), cardiovascular (aHR 1.08, 95% CI 1.05-1.12), and all causes (aHR 1.13, 95% CI 1.10-1.16) relative to nonprofit hospitals. Public hospitals were associated with higher risk of 90-day readmission for heart failure (aHR 1.08, 95% CI 1.02-1.13) relative to nonprofit hospitals.</p><p><strong>Conclusions: </strong>For-profit and public hospitals were associated with higher in-hospital mortality and 90-day readmission for various causes compared with nonprofit hospitals. These findings suggest that hospital-level factors may contribute to disparities in STEMI outcomes and warrant further investigation.</p>","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":" ","pages":"107452"},"PeriodicalIF":3.5,"publicationDate":"2026-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147760193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validity of international classification of diseases, tenth revision codes in diagnosing myocardial infarction subtypes.","authors":"Connor Suscha, Elaine Luterstein, Nhi Tong, Seán Murphy, Avanthi Raghavan, Yuxi Liu, Jason H Wasfy, Pradeep Natarajan, James L Januzzi, Cian P McCarthy","doi":"10.1016/j.ahj.2026.107447","DOIUrl":"10.1016/j.ahj.2026.107447","url":null,"abstract":"<p><p>International Classification of Diseases, Tenth Revision (ICD‑10) codes are commonly used for identifying myocardial infarction (MI) in clinical research and increasingly used to capture events in clinical trials, however, their accuracy for distinguishing MI subtypes is uncertain. In a study of 24,524 individuals undergoing troponin testing, type 1 MI ICD‑10 codes showed moderate sensitivity (53%) but high specificity (99%), whereas the ICD-10 codes for type 2 MI and types 3-5 MI demonstrated extremely low sensitivity (3% and 0%, respectively) despite high specificity (99%). These data suggest that ICD‑10 codes for each individual MI subtype have such low sensitivity that they may not reliably and accurately identify these MI subtypes in clinical research or in quality metrics and value-based programs.</p>","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":" ","pages":"107447"},"PeriodicalIF":3.5,"publicationDate":"2026-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147760221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"External validation of organ perfusion pressure as a prognostic marker in cardiogenic shock.","authors":"Pier Paolo Bocchino, Jorge A Ortega-Hernández, Luca Baldetti, Guglielmo Gallone, Giulio Cacioli, Fabio Sbaraglia, Giampaolo Luzi, Mariagiulia Festi, Francesca Pirone, Beatrice Peveri, Simone Frea, Filippo Angelini, Lorenzo Nocera, Héctor González-Pacheco, Arturo Arzate-Ramirez, Salvador Mendoza-Garcia, Marco Metra, Jaime Hernández-Montfort, Alexandra Arias-Mendoza, Anna Mara Scandroglio, Gaetano Maria De Ferrari","doi":"10.1016/j.ahj.2026.107448","DOIUrl":"https://doi.org/10.1016/j.ahj.2026.107448","url":null,"abstract":"<p><strong>Background: </strong>The organ perfusion pressure (OPP) is as a surrogate for end-organ hypoperfusion and was shown to predict outcomes in a multicenter cohort of cardiogenic shock (CS) patients. This investigation was conducted to externally validate the independent prognostic efficacy of admission OPP in predicting in-hospital mortality in CS.</p><p><strong>Methods: </strong>This was a retrospective analysis of a multicentre international registry that enrolled consecutive patients admitted for CS from July 2023 to October 2024. Only patients with CS related to heart failure (HF) or acute myocardial infarction (AMI) were included. Admission OPP was calculated as the difference between mean arterial pressure and central venous pressure. The primary outcome was in-hospital all-cause death.</p><p><strong>Results: </strong>621 patients were considered (mean age 62 ± 13 years; 138 [22.2%] female): 518 (83.4%) patients presented with SCAI stage ≥ C severity. In-hospital all-cause death occurred in 247 (39.8%) individuals. As compared to survivors, non-survivors had significantly lower OPP (59 mmHg [IQR 49-69 mmHg] vs 70 mmHg [60-80 mmHg], p-value<0.001). In univariable analysis, low OPP (< 57 mmHg) was associated with significantly higher in-hospital all-cause mortality (OR 3.20 [95%CI 2.25-4.56], p-value<0.001); this result was consistent across both AMI-CS and HF-CS cohorts. In a multivariable logistic regression analysis including age, diabetes, SCAI stage, Sequential Organ Failure Assessment score, creatinine, lactates, vasoactive inotropic score, OPP, central venous pressure and cardiac arrest, lower OPP significantly predicted the primary outcome (OR per mmHg decrease: 1.03 [95%CI 1.01-1.06], p-value=0.020). The C-index for OPP as a predictor of in-hospital mortality was 0.691 (slope=1.01; intercept=0.01).</p><p><strong>Conclusions: </strong>In this multicentre CS cohort, admission OPP was an independent prognostic marker of in-hospital mortality, irrespective of underlying CS aetiology. Its inherent simplicity and demonstrated clinical robustness may support its integration into risk stratification and CS protocols.</p>","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":" ","pages":"107448"},"PeriodicalIF":3.5,"publicationDate":"2026-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147721611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing In-Hospital Mortality Prediction for Acute Myocardial Infarction: an analysis from the American Heart Association Get-With-the-Guidelines Coronary Artery Disease Registry.","authors":"Juan Zhao, Haoyun Hong, Alexander Fanaroff, Sophia Zhong, Kelvin N V Bush, Christopher Granger, Nicole Huber, Cynthia A Jackevicius, Ingrid Kindipan, Shen Li, Paula Lewis, Asishana Osho, Jeffrey Sather, Stephen L Sigal, Kathie Thomas, Zhao Ni, Jennifer L Hall, Alice K Jacobs, Abhinav Goyal","doi":"10.1016/j.ahj.2026.107445","DOIUrl":"https://doi.org/10.1016/j.ahj.2026.107445","url":null,"abstract":"<p><strong>Background: </strong>Cardiovascular disease remains the leading cause of mortality worldwide, with acute myocardial infarction (AMI) contributing to over 100,000 deaths annually in the United States. Accurate risk stratification for in-hospital mortality is essential for guiding clinical decisions, improving outcomes, and optimizing hospital resources. However, existing models often rely on limited predictor sets, outdated data, and linear methods that may not reflect current clinical practice.</p><p><strong>Objective: </strong>To develop and validate a contemporary in-hospital mortality risk model for AMI patients incorporating clinical, demographic, and social determinants of health and to compare performance against the legacy ACTION Registry-GWTG model.</p><p><strong>Methods: </strong>We utilized data from the American Heart Association (AHA) Get with The Guidelines®-Coronary Artery Disease (GWTG-CAD) Registry. Patients with AMI admitted between October 1, 2019, and December 31, 2022 (201,191 patients from 605 hospitals) were used to develop the in-hospital mortality prediction model. 70,302 patients admitted in 2023 served as an independent validation cohort. We incorporated 27 predictors and benchmarked against the legacy ACTION Registry-GWTG model. Subgroup and sensitivity analyses assessed model performance across sex, race/ethnicity, STEMI status, and time period.</p><p><strong>Results: </strong>The Light Gradient Boosting Machine (LightGBM) -based GWTG-CAD model achieved the highest discrimination (AUROC 0.874, 95% CI: 0.867-0.880) and superior calibration across subgroups, outperforming the ACTION Registry-GWTG model (AUROC 0.859, 95% CI: 0.852 - 0.867). Comorbidities, transportation method, and community-level socioeconomic factors contributed meaningful predictive value beyond traditional predictors. The generalized linear mixed model (GLMM, AUROC 0.865) provided interpretable odds ratios and calibrated probability estimates suitable for risk-adjusted benchmarking and quality improvement.</p><p><strong>Conclusion: </strong>The GWTG-CAD model suite advances AMI mortality prediction through two complementary approaches: the LightGBM model offers superior discrimination for identifying high-risk patients across diverse subgroups, while the GLMM provides a transparent tool for institutional benchmarking and quality improvement. Broader external validation is needed before clinical deployment.</p>","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":" ","pages":"107445"},"PeriodicalIF":3.5,"publicationDate":"2026-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147697071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Information for Readers","authors":"","doi":"10.1016/S0002-8703(26)00037-2","DOIUrl":"10.1016/S0002-8703(26)00037-2","url":null,"abstract":"","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":"294 ","pages":"Article 107375"},"PeriodicalIF":3.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146184730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A multicenter trial to test pitavastatin calcium in youth with combined dyslipidemia of obesity: Design, implementation, challenges, and responses","authors":"Sarah D. de Ferranti MD MPH ,&nbsp;Jessica E. Teng MPH ,&nbsp;Silva A. Arslanian MD ,&nbsp;Andrew M. Atz MD ,&nbsp;Julie A. Brothers MD ,&nbsp;Mark J. Cartoski MD ,&nbsp;D’Andrea R. Freemon RN, MSN ,&nbsp;Sheela N. Magge MD MSCE ,&nbsp;William T. Mahle MD ,&nbsp;Michele Mietus-Snyder MD ,&nbsp;Amy Peterson MD MS ,&nbsp;Geetha Raghuveer MD MPH ,&nbsp;Mark W. Russell MD ,&nbsp;Amy S. Shah ,&nbsp;Craig A. Sponseller MD ,&nbsp;Mario Stylianou PhD ,&nbsp;Felicia L. Trachtenberg PhD ,&nbsp;Elaine M. Urbina MD MS ,&nbsp;Adam L. Ware MD ,&nbsp;Justin Zachariah MD MPH ,&nbsp;Brian W. McCrindle MD MPH","doi":"10.1016/j.ahj.2025.107327","DOIUrl":"10.1016/j.ahj.2025.107327","url":null,"abstract":"<div><h3>Background</h3><div>Combined dyslipidemia of obesity (CDO) is a prevalent atherogenic lipid disorder characterized by high TG, low HDL, high non-HDL, and a preponderance of small LDL particles. Lifestyle modification is the mainstay of treatment but is often insufficient; a pharmacologic approach could augment care but has not been rigorously evaluated.</div></div><div><h3>Methods</h3><div>The dyslipidemia of obesity intervention in teens (DO IT!) Trial was a 2-year randomized controlled double-blind study designed to measure the effect and safety profile of pitavastatin calcium vs placebo on vascular measures of early atherosclerosis, and standard and advanced lipid profiles in children and adolescents with CDO. We present the rationale, design, and study procedures, and share challenges, responses, and lessons learned.</div></div><div><h3>Results</h3><div>Participants were recruited from 17 sites; goal 177, with 122 consented (68.9%). Facilitators to recruitment included familiarity of site investigators with CDO management, relationship with local obesity programs, and study incentives. Barriers included 2-year study duration, number of study visits, and COVID-19 pandemic effects. The research team added recruitment sites, expanded eligibility, shared educational and promotional materials, and bolstered site engagement but enrollment was insufficient, and the trial was stopped early.</div></div><div><h3>Conclusions</h3><div>The DO IT! Trial was the first to evaluate effects of pitavastatin vs placebo on vascular measures, lipid outcomes and potential adverse effects. Recruitment challenges limited the study sample, but findings may still inform cardiovascular prevention. Future studies are more likely to be more successful with early patient-family input, shorter study duration, and fewer study visits integrated with clinical care close to home.</div><div>ClinicalTrials.gov identifier: NCT02956590.</div></div>","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":"294 ","pages":"Article 107327"},"PeriodicalIF":3.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145772937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Coronary computed tomography angiography versus invasive coronary angiography for interventional triage in acute coronary syndrome: Design of the randomized TRACTION trial","authors":"Mathias Holm Sørgaard MD, PhD ,&nbsp;Andreas Torp Kristensen MD ,&nbsp;Kristian Eskesen MD, PhD ,&nbsp;Klaus Fuglsang Kofoed MD, PhD, DMSc ,&nbsp;Jesper James Linde MD, PhD ,&nbsp;Henning Kelbæk ,&nbsp;Michael Ottesen MD, PhD ,&nbsp;Keld Neland MD, PhD ,&nbsp;Charlotte Kragelund MD, PhD ,&nbsp;Mette Lykke Norgaard Bertelsen MD, PhD ,&nbsp;Jens Dahlgaard Hove MD, PhD ,&nbsp;Gorm Mørk MD, PhD ,&nbsp;Ole Peter Kristiansen MD, PhD ,&nbsp;Thomas Engstrøm MD, PhD, DMSc ,&nbsp;Jacob Thomsen Lønborg MD, PhD, DMSc ,&nbsp;Jørgen Tobias Kühl MD, PhD, DMSc ,&nbsp;Signe Stelling Risom RN, PhD ,&nbsp;Paul Blanche MSc, PhD ,&nbsp;Niels Thue Olsen MD, PhD","doi":"10.1016/j.ahj.2025.107325","DOIUrl":"10.1016/j.ahj.2025.107325","url":null,"abstract":"<div><h3>Purpose</h3><div>In patients admitted with acute coronary syndrome, invasive coronary angiography (ICA) is performed to determine which patients need revascularization. Coronary computed tomography angiography (CCTA) offers a widely available, non-invasive alternative that could reduce patient discomfort, procedural risks, and healthcare costs. The current trial aims to determine whether CCTA is noninferior to ICA in determining the interventional strategy for patients admitted with non-ST elevation acute coronary syndrome (NSTE-ACS)(<span><span>Central Illustration</span></span>).</div></div><div><h3>Methods</h3><div>TRACTION (Team-based Interventional Triage in Acute Coronary Syndrome Based on Noninvasive Coronary Computed Tomography Angiography Versus Invasive Coronary Angiography) is a multicenter, randomized, open-label, noninferiority trial enrolling 2,300 patients. Patients hospitalized with non-ST elevation myocardial infarction or unstable angina with ischemic changes on ECG will be randomized 1:1 to CCTA vs ICA (standard of care). In the CCTA group, a Coronary Team reviews the CCTA and clinical information to determine the interventional strategy. The primary composite endpoint is major adverse cardiac events at 1 year, comprised of all-cause mortality, nonfatal myocardial infarction, hospitalization due to refractory angina, or hospitalization due to heart failure. Secondary outcomes include cardiovascular death, revascularization, symptom status, procedure-related adverse events, and resource utilization. The trial is designed to demonstrate noninferiority if the 95% confidence interval excludes an absolute risk difference of the primary endpoint larger than 5%.</div></div><div><h3>Perspectives</h3><div>If CCTA is shown to be noninferior to ICA in patients admitted with NSTE-ACS, CCTA could become the preferred management in a large group of patients. This could result in fewer patients exposed to invasive procedures and improved resource utilization.</div><div>ClinicalTrials.gov identifier: NCT06101862</div></div>","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":"294 ","pages":"Article 107325"},"PeriodicalIF":3.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145707173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to the letter: Another perspective on democracy, healthcare and the public good","authors":"Richard C. Becker MD","doi":"10.1016/j.ahj.2025.107336","DOIUrl":"10.1016/j.ahj.2025.107336","url":null,"abstract":"","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":"294 ","pages":"Article 107336"},"PeriodicalIF":3.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145846506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dual versus monotherapy with SGLT2 inhibitor and GLP-1 receptor agonist: PRECIDENTD pragmatic randomized trial","authors":"Deborah J. Wexler MD, MSc ,&nbsp;Lindsay S. Mayberry PhD ,&nbsp;Lyndsay A. Nelson PhD ,&nbsp;Jeremy Lema-Driscoll BA ,&nbsp;Ligia C. Flores MS ,&nbsp;Maureen Malloy BS ,&nbsp;Jean G. MacFadyen BA ,&nbsp;Joseph Shen BS ,&nbsp;Elaine Zaharris BA ,&nbsp;Harsha Karanchi MD ,&nbsp;Ranee Chatterjee MD, MPH ,&nbsp;Catherine P. Benziger MD, MPH ,&nbsp;Jake E. Decker MD ,&nbsp;Rita Kalyani MD, MHS ,&nbsp;Camila Manrique-Acevedo MD, MHS ,&nbsp;Jacqueline Lonier MD ,&nbsp;Edward Simeone MA ,&nbsp;Kathleen Mieras BSAH ,&nbsp;Amanda R.O. Siqueira MD ,&nbsp;Russell L. Rothman MD, MPP ,&nbsp;Brendan M. Everett MD, MPH","doi":"10.1016/j.ahj.2025.107332","DOIUrl":"10.1016/j.ahj.2025.107332","url":null,"abstract":"<div><h3>Background</h3><div>Dual therapy with sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) is frequently recommended. We compared rates of medication initiation and discontinuation between participants assigned to treatment with a single medication class or dual therapy in the feasibility phase of the PREvention of CardIovascular and DiabEtic kidNey disease in Type 2 Diabetes (PRECIDENTD) pragmatic trial.</div></div><div><h3>Methods</h3><div>PRECIDENTD randomly assigned participants with type 2 diabetes (T2D) and ASCVD or high ASCVD risk to fill prescriptions for SGLT2i, GLP-1RA, or dual therapy (1:1:1) using their own insurance. Analyses compared medication fill and discontinuation rates of assigned medication(s), Patient-Reported Outcomes Measurement Information System (PROMIS) Physical and Mental Health Scores, and Modified Kansas City Cardiomyopathy Questionnaire (mKCCQ)-12 between the combined monotherapy (SGLT2i or GLP-1RA) and dual therapy (SGLT2i and GLP-1RA) groups.</div></div><div><h3>Results</h3><div>This report includes 173 insured participants [median age 67 years (IQR 62, 72), 46% female, 35% non-White, 67% with ASCVD]; 113 assigned to monotherapy and 60 to dual therapy. Monotherapy vs dual therapy fill rates were 84% vs 53% (<em>P</em> &lt; .001) 4 months after randomization and 87% vs 68% overall (<em>P</em> = .004) during 10-month median follow-up. Of those who filled medication, 22% in monotherapy and 49% in dual therapy discontinued a study medication (<em>P</em> = .002), mostly due to side effects. PROMIS and mKCCQ-12 scores showed no change.</div></div><div><h3>Conclusions</h3><div>Despite efforts to facilitate medication uptake in the feasibility phase of the PRECIDENTD pragmatic trial, barriers to initiation and ongoing use challenge the use of combination SGLT2i and GLP-1RA in T2D.</div></div><div><h3>Trial registration</h3><div><span><span>ClinicalTrials.gov</span><svg><path></path></svg></span>, NCT05390892, <span><span>https://clinicaltrials.gov/study/NCT05390892</span><svg><path></path></svg></span>.</div></div>","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":"294 ","pages":"Article 107332"},"PeriodicalIF":3.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145848819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on: Yoga vs regular exercise for atrial fibrillation: Design considerations for the yoga-AF randomized trial","authors":"Kotina Shridevi MD ,&nbsp;Rachna Rohtagi MS ,&nbsp;Kanishka Harariya MBBS ,&nbsp;Hariharan Srinivasan MD","doi":"10.1016/j.ahj.2025.107333","DOIUrl":"10.1016/j.ahj.2025.107333","url":null,"abstract":"","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":"294 ","pages":"Article 107333"},"PeriodicalIF":3.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145846542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}